Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.
Norwich Medical School, University of East Anglia, Norwich, England.
JAMA Intern Med. 2021 Feb 1;181(2):168-178. doi: 10.1001/jamainternmed.2020.5938.
Nearly half of the older adult population has diabetes or a high-risk intermediate glycemic category, but we still lack trial evidence for effective type 2 diabetes prevention interventions in most of the current high-risk glycemic categories.
To determine whether a group-based lifestyle intervention (with or without trained volunteers with type 2 diabetes) reduced the risk of progression to type 2 diabetes in populations with a high-risk glycemic category.
DESIGN, SETTING, AND PARTICIPANTS: The Norfolk Diabetes Prevention Study was a parallel, 3-arm, group-based, randomized clinical trial conducted with up to 46 months of follow-up from August 2011 to January 2019 at 135 primary care practices and 8 intervention sites in the East of England. We identified 141 973 people at increased risk of type 2 diabetes, screened 12 778 (9.0%), and randomized those with a high-risk glycemic category, which was either an elevated fasting plasma glucose level alone (≥110 and <126 mg/dL [to convert to millimoles per liter, multiply by 0.0555]) or an elevated glycated hemoglobin level (≥6.0% to <6.5%; nondiabetic hyperglycemia) with an elevated fasting plasma glucose level (≥100 to <110 mg/dL).
A control arm receiving usual care (CON), a theory-based lifestyle intervention arm of 6 core and up to 15 maintenance sessions (INT), or the same intervention with support from diabetes prevention mentors, trained volunteers with type 2 diabetes (INT-DPM).
Type 2 diabetes incidence between arms.
In this study, 1028 participants were randomized (INT, 424 [41.2%] [166 women (39.2%)]; INT-DPM, 426 [41.4%] [147 women (34.5%)]; CON, 178 [17.3%] [70 women (%39.3)]) between January 1, 2011, and February 24, 2017. The mean (SD) age was 65.3 (10.0) years, mean (SD) body mass index 31.2 (5) (calculated as weight in kilograms divided by height in meters squared), and mean (SD) follow-up 24.7 (13.4) months. A total of 156 participants progressed to type 2 diabetes, which comprised 39 of 171 receiving CON (22.8%), 55 of 403 receiving INT (13.7%), and 62 of 414 receiving INT-DPM (15.0%). There was no significant difference between the intervention arms in the primary outcome (odds ratio [OR], 1.14; 95% CI, 0.77-1.7; P = .51), but each intervention arm had significantly lower odds of type 2 diabetes (INT: OR, 0.54; 95% CI, 0.34-0.85; P = .01; INT-DPM: OR, 0.61; 95% CI, 0.39-0.96; P = .033; combined: OR, 0.57; 95% CI, 0.38-0.87; P = .01). The effect size was similar in all glycemic, age, and social deprivation groups, and intervention costs per participant were low at $153 (£122).
The Norfolk Diabetes Prevention lifestyle intervention reduced the risk of type 2 diabetes in current high-risk glycemic categories. Enhancing the intervention with DPM did not further reduce diabetes risk. These translatable results are relevant for current diabetes prevention efforts.
ISRCTN Registry Identifier: ISRCTN34805606.
近一半的老年人口患有糖尿病或高风险的中间血糖类别,但我们在大多数当前高风险血糖类别中仍然缺乏有效的 2 型糖尿病预防干预措施的试验证据。
确定基于群体的生活方式干预(有无 2 型糖尿病的受过培训的志愿者)是否降低了高风险血糖类别的人群进展为 2 型糖尿病的风险。
设计、设置和参与者:诺福克糖尿病预防研究是一项平行的、3 臂、基于群体的随机临床试验,从 2011 年 8 月至 2019 年 1 月,在英格兰东部的 135 个初级保健实践和 8 个干预地点进行,最长随访时间为 46 个月。我们确定了 141973 名有 2 型糖尿病风险的人,筛选了 12778 人(9.0%),并对高风险血糖类别(单独空腹血糖水平升高[≥110 且 <126mg/dL(转换为毫摩尔/升,乘以 0.0555]或糖化血红蛋白水平升高[≥6.0%至<6.5%;非糖尿病性高血糖]伴有空腹血糖水平升高[≥100 且 <110mg/dL]的人进行随机分组。
对照组接受常规护理(CON),6 个核心和最多 15 个维持课程的基于理论的生活方式干预组(INT),或具有 2 型糖尿病预防导师支持的相同干预组(由受过培训的志愿者组成)(INT-DPM)。
各组之间的 2 型糖尿病发病率。
在这项研究中,共有 1028 名参与者被随机分组(INT,424 [41.2%] [166 名女性(39.2%)];INT-DPM,426 [41.4%] [147 名女性(34.5%)];CON,178 [17.3%] [70 名女性(39.3%)]),时间为 2011 年 1 月 1 日至 2017 年 2 月 24 日。平均(SD)年龄为 65.3(10.0)岁,平均(SD)体重指数 31.2(5)(计算为千克除以米的平方),平均(SD)随访时间为 24.7(13.4)个月。共有 156 名参与者进展为 2 型糖尿病,其中 CON 组 171 人中有 39 人(22.8%),INT 组 403 人中有 55 人(13.7%),INT-DPM 组 414 人中有 62 人(15.0%)。干预组与对照组在主要结局(比值比[OR],1.14;95%置信区间,0.77-1.7;P = .51)之间无显著差异,但每个干预组发生 2 型糖尿病的可能性均较低(INT:OR,0.54;95%置信区间,0.34-0.85;P = .01;INT-DPM:OR,0.61;95%置信区间,0.39-0.96;P = .033;联合:OR,0.57;95%置信区间,0.38-0.87;P = .01)。在所有血糖、年龄和社会贫困组中,效果大小相似,每个参与者的干预成本为 153 美元(122 英镑)。
诺福克糖尿病预防生活方式干预降低了当前高风险血糖类别的 2 型糖尿病风险。通过增强与 DPM 的干预并没有进一步降低糖尿病风险。这些可转化的结果与当前的糖尿病预防工作有关。
ISRCTN 登记号:ISRCTN34805606。